Applying Molecular and Functional Genomics to Identify Biomarkers for Diagnosing and Treating Cancer

应用分子和功能基因组学来识别诊断和治疗癌症的生物标志物

• 批准号: 10249257
• 负责人: Kiranmai Gumireddy
• 金额: $ 13.82万
• 依托单位: WISTAR INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-16 至 2021-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10249257
• 关键词: Adoption; Area; Award; Bioinformatics; Biological Assay; Biological Markers; Biopsy; Cancer Patient; Cells; Cellular biology; Clinical; Collaborations; Diagnosis; Ensure; Funding; Gene Expression Profile; Genomics; Glioblastoma; Goals; Individual; Industry; Journals; Knowledge; Legal patent; Malignant Neoplasms; Malignant neoplasm of lung; Methods; Molecular; Molecular Biology; Molecular Biology Techniques; Nature; Neoplasm Metastasis; Non-Small-Cell Lung Carcinoma; Paper; Patients; Peripheral Blood Mononuclear Cell; Plasma; Protocols documentation; Publications; Publishing; RNA; RNA Editing; Research; Research Personnel; Research Project Grants; Risk; Role; Sampling; Screening for cancer; Specialist; T cell receptor repertoire sequencing; Techniques; Technology; The Wistar Institute; Translational Research; Tumor Antigens; Work; base; biobank; biomarker signature; blood-based biomarker; career; circulating biomarkers; design; effective therapy; experience; functional genomics; genetic signature; genomic data; improved; interest; nano-string; novel; operation; personalized medicine; success; tumorigenesis

SUMMARY This application will support an exceptional Research Specialist who is essential to the scientific direction, operation, and enhancement of a productive research group. The Research Specialist and Unit Director have worked together since 2009, closely since 2017. The major goal of the Unit Director’s group is to develop inexpensive, non-invasive methods that can identify individuals who are at risk of non-small cell lung cancer and use the information obtained to improve therapy. As part of this effort, the Research Specialist is responsible for collecting and maintaining The Wistar Institute biorepository of 3,350 non-small cell lung cancer patient samples, including PBMC, PAXgene, and plasma. The Director’s group also manages Genomics and Bioinformatics Cores, which support ~15 NCI-funded research projects. Last, the Unit Director and Research Specialist collaborate with other Wistar investigators and industry to: identify a gene expression signature that can subclassify glioblastoma, characterize a potential new tumor antigen generated by the fusion of 2 LNC- RNAs, and understand the role of A-to-I RNA editing in metastasis. The Research Specialist has expertise in cell and molecular biology and extensive experience in multiple genomics and cell biology techniques. She also has a strong interest in translational research and has been able to apply the knowledge generated to design more effective therapies for lung cancer and glioblastoma. She is first author on 17 of the 26 papers she has published and on 9 of the 17 papers published during her 12-year tenure at Wistar. Many are in highly ranked journals including Nature Cell Biology, PNAS, EMBO, and Cell. She is listed on 5 U.S. patents. The Research Specialist’s expertise in a wide variety of molecular biology techniques is critical for the success of all main projects. It makes her ideally suited to conduct the studies on developing lung cancer genetic and biomarker signatures using genomic based assays; it also enables her to identify areas where improvements/changes are needed and independently develop protocols to improve the variety of assays employed. Since the Showe lab has been the primary developer of new genomics technologies for adoption by the Genomics Core, the Research Specialist’s background is essential for being able to develop these new platforms, including TCR-seq, the assessment of various platforms for single cell genomics, and the implementation of various NanoString technologies. For most work, the Research Specialist is the primary interface with Bioinformatics, ensuring that genomic data is correctly interpreted for analysis. The Research Specialist is essential not only for completing the proposed work of the next five years, but also for identifying new directions and new research and clinical collaborations. In summary, this award will allow the Research Specialist to continue making significant contributions to identifying circulating biomarkers for early cancer detection and to understanding the mechanisms of metastasis and oncogenesis. It will advance the identification of circulating biomarkers for lung cancer, support multiple NCI-funded groups via the Genomics Core, and enhance novel collaborations.

总结 此应用程序将支持一个特殊的研究专家谁是必不可少的科学方向， 操作，并加强生产研究小组。研究专家和单位主任有 从2009年开始合作，从2017年开始密切合作。股长小组的主要目标是发展 廉价，非侵入性的方法，可以识别有非小细胞肺癌风险的个体， 利用获得的信息来改善治疗。作为这项工作的一部分，研究专家负责 用于收集和维护3，350名非小细胞肺癌患者的Wistar研究所生物储存库 样本，包括PBMC、PAXgene和血浆。主任的小组还管理基因组学和 生物信息学核心，支持约15个NCI资助的研究项目。最后，单位主任和研究 专家与其他Wistar研究人员和行业合作：鉴定基因表达特征， 可以对胶质母细胞瘤进行亚分类，表征由2个LNC- RNA，并了解A-to-I RNA编辑在转移中的作用。研究专家具有以下专业知识： 细胞和分子生物学以及多种基因组学和细胞生物学技术的丰富经验。她还 对转化研究有浓厚的兴趣，并能够将所产生的知识应用于设计 更有效的治疗肺癌和胶质母细胞瘤的方法。她是26篇论文中17篇的第一作者 在她12年的Wistar任期内发表的17篇论文中，有9篇发表在她的论文上。许多人在高排名 期刊包括Nature Cell Biology、PNAS、EMBO和Cell。她拥有5项美国专利。研究 专家在各种分子生物学技术方面的专业知识对于所有主要的生物学技术的成功至关重要。 项目这使她非常适合进行肺癌遗传和生物标志物的研究 使用基于基因组的测定的签名;它还使她能够确定改进/变化的领域， 需要并独立开发方案来改进所采用的测定方法的多样性。自从肖实验室 一直是新基因组学技术的主要开发者， 专家的背景对于能够开发这些新平台至关重要，包括TCR-seq， 评估单细胞基因组学的各种平台，以及各种NanoString的实施 技术.对于大多数工作，研究专家是生物信息学的主要接口，确保 基因组数据被正确地解释用于分析。研究专家不仅对完成 未来五年的工作建议，而且还确定了新的方向和新的研究和临床 合作。总之，该奖项将使研究专家继续做出重大贡献， 有助于识别早期癌症检测的循环生物标志物，并了解 转移和肿瘤发生的机制。它将促进肺循环生物标志物的鉴定， 癌症，通过基因组学核心支持多个国家癌症研究所资助的团体，并加强新的合作。